Últimas noticias sobre ProQR Therapeutics (NASDAQ:PRQR) Bolsa

ProQR Therapeutics

ProQR Therapeutics NV is a biopharmaceuticals company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa.

ProQR Therapeutics N.V. - Ordinary Shares

ProQR Therapeutics NV

WIIM

PRQR

Pro QR Therapeutics shares are trading higher after the company reported better-than-expected Q1 EPS results.

Earnings

News

ProQR Therapeutics Q1 2024 GAAP EPS €(0.03) Beats €(0.11) Estimate, Sales €6.305M Miss €11.460M Estimate, €96.2M Cash Position As Of End Of Q2 Providing Runway Into Mid-2026

ProQR Therapeutics NV (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRQR#NASDAQ">PRQR</a>) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it will participate in the RNA Editing Summit, June 18-20, 2024, in Boston, Massachusetts. &nbsp;
As part of the conference program, Gerard Platenburg, Chief Scientific Officer and Co-Founder, ProQR Therapeutics, will present on June 20, 2024 at 2:00pm ET:

Biotech

General

ProQR Presents Its Axiomer RNA Editing Technology At RNA Editing Summit

Chardan Capital analyst Keay Nakae maintains ProQR Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRQR#NASDAQ">PRQR</a>) with a Buy and maintains $2.5 price target.

Price Target

Analyst Ratings

Chardan Capital Maintains Buy on ProQR Therapeutics, Maintains $2.5 Price Target

HC Wainwright &amp; Co. analyst Andrew Fein reiterates ProQR Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRQR#NASDAQ">PRQR</a>) with a Buy and maintains $5 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on ProQR Therapeutics, Maintains $5 Price Target

Guidance

Health Care

ProQR Therapeutics' Cash And Cash Equivalents And Short Term Financial Assets Of €102.7M As Of End Of Q1 Provides Runway Into Mid-2026

ProQR Therapeutics Q1 2024 GAAP EPS €(0.09) Misses €(0.07) Estimate, Sales €4.450M Beat €3.144M Estimate

<ul>
<li>ProQR scientists report for the first time in the ADAR RNA editing field in vivo proof of target engagement (RNA editing) leading to meaningful changes in biomarkers in NHPs using Axiomer&#x2122; RNA Editing Oligonucleotides</li>
<li>Preclinical proof of concept for the Company's AX-0810 program targeting NTCP for cholestatic diseases presented at ASGCT Annual Meeting
<ul>
<li>Management webinar May 9, 2024 at 8:00 am EDT</li>
</ul>
</li>
</ul>
LEIDEN, Netherlands &amp; CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRQR#NASDAQ">PRQR</a>) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced new preclinical data for its proprietary Axiomer&#x2122; RNA editing technology platform, including the first preclinical proof of concept data for its AX-0810 pipeline program for cholestatic diseases targeting NTCP. The data are being presented at a poster session today at the American Society of Gene &amp; Cell Therapy (ASGCT) Annual Meeting, May 7-11, 2024, in Baltimore, Maryland.
"Our Axiomer ADAR RNA editing data at ASGCT show the exciting potential of our technology and for the first time in the field we report proof of target engagement leading to meaningful changes in biomarkers in NHPs," said Gerard Platenburg, Chief Scientific Officer and co-founder, ProQR. "In our AX-0810 program targeting NTCP for cholestatic diseases, we have demonstrated preclinical proof of concept showing that Axiomer RNA editing oligonucleotides can have a meaningful effect on levels of serum biomarker bile acid. We believe this is a significant derisking step as we approach the clinic as our NHP studies closely resemble the design of the first in human trial that will focus on target engagement and biomarkers. We look forward to sharing translational data for our AX-0810 program and to announcing our clinical program candidate later this year, as we progress to enter the clinic in late 2024/early 2025."

ProQR Gives Preclinical Proof Of Concept Data For AX-0810 Axiomer RNA Editing Program Targeting NTCP For Cholestatic Diseases

Events

ProQR Therapeutics To Present On Axiomer RNA Editing At ASGCT 27th Annual Meeting

The company announced it has again successfully defended against opposition filed against a key patent for its ADAR-mediated RNA editing platform Axiomer.
The opposition was filed in June 2021 with the European Patent Office (EPO) by a strawman against ProQR&#39;s granted patent&nbsp;<a href="https://www.globenewswire.com/Tracker?data=2Ct1VlHTN7s9kKLzuYjjceoprNCVAnRgUXOy9TbpbOkved0Wb0LKvKfwvcte2z9f0uiOJYBnah3BwVLHtWsFlh14ptX8M2hNCCt0TV84gUnQybAQSnfAzumrPTbCoa85TdnYF5Bje4KPY3O1eTz0OA==" target="_blank">EP 3 507 366 B1</a>,&nbsp;which relates to editing oligonucleotides that have certain chemical modifications in the base and/or ribose sugar to increase stability and recruit endogenous ADAR to edit the target adenosine. This patent is part of ProQR&#39;s intellectual property estate surrounding its Axiomer RNA editing platform and the current generation of its molecules. The Opposition Division of the EPO held a public hearing on April 17, 2024, and ruled such that ProQR&#39;s strong IP position on chemically modified editing oligonucleotides was maintained.
The patent contains broad platform claims including: &quot;An antisense oligonucleotide (AON) capable of forming a double stranded complex with a target RNA sequence in a cell, preferably a human cell, for the deamination of a target adenosine in the target RNA sequence by an ADAR enzyme present in the cell&hellip;&quot;, which protects ProQR&#39;s proprietary ADAR mediated RNA editing platform Axiomer.
&quot;This decision further supports the confidence we have in the broad scope conferred by our IP estate protecting our proprietary Axiomer ADAR-mediated RNA editing technology platform, and the use of chemically modified oligonucleotides to increase stability and recruit endogenous ADAR to edit the target adenosine,&quot; said Ren&eacute; Beukema, Chief Corporate Development Officer and General Counsel. &quot;Given the importance and value of our IP portfolio, we intend to continue to defend against such challenges and remain confident in our leading position, as we progress our science, platform, and pipeline.&quot;
ProQR invented the use of endogenous ADAR in RNA editing in 2014 and filed a first patent application in that same year.&nbsp;

ProQR Therapeutics Says It Achieved Successful Defense of New Challenge To Its Axiomer IP Portfolio

Chardan Capital analyst Keay Nakae maintains ProQR Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRQR#NASDAQ">PRQR</a>) with a Buy and raises the price target from $2 to $2.5.

Chardan Capital Maintains Buy on ProQR Therapeutics, Raises Price Target to $2.5

ProQR Therapeutics shares are trading higher after the company reported a year-over-year increase in FY23 EPS results.

ProQR Therapeutics' 2023 Cash And Cash Equivalents Of €118.9M Is Expected To Provide Cash Runway Into Mid-2026

ProQR Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRQR#NASDAQ">PRQR</a>) reported quarterly losses of $(0.38) per share. This is a 61.09 percent increase over losses of $(0.97) per share from the same period last year.

ProQR Therapeutics FY EPS $(0.38) Up From $(0.97) YoY

Legal

ProQR Says Japanese Axiomer Patent Upheld Following Opposition Against Its IP Estate For ADAR-Mediated RNA Editing

ProQR Therapeutics Highlights New Platform Data From Presentation On Axiomer RNA Editing Technology, Company Says Platform Demonstrates Robust In Vivo Editing Capabilities Reporting Up To 70% Editing Of ACTB In Liver Of Non-human Primates (NHPS) And Mice

<ul>
<li>Platform demonstrates robust&nbsp;in vivo&nbsp;editing capabilities reporting up to&nbsp;70%&nbsp;editing of ACTB in the liver of non-human primates (NHPs) and mice</li>
<li>Functional effect demonstrated in mice&nbsp;in vivo&nbsp;via modulation of ANGPLT3 protein properties leading to favorable increase in LPL enzymatic activity and meaningful impact of biomarkers</li>
<li>Additional data to be presented throughout 2024, including&nbsp;in vitro&nbsp;and&nbsp;in vivo&nbsp;data for pipeline programs AX-0810 for Cholestatic diseases targeting NTCP and AX-1412 for Cardiovascular diseases targeting B4GALT1</li>
</ul>

ProQR Highlights New Platform Data from Presentation on Axiomer RNA Editing Technology at Deaminet 2024

Shares of KeyCorp (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/key#NYSE">KEY</a>) moved lower during Thursday&rsquo;s session after the company reported fourth-quarter financial results.
Revenues of $1.538 billion, down 19.0% Y/Y, slightly topped the consensus of $1.532 billion. Adjusted EPS of 25 cents topped the street view of 23 cents.
KeyCorp shares fell 5.4% to $13.10 on Thursday.
Here are some other stocks moving in today&#39;s mid-day session.
<h3>Gainers</h3>
<ul>
<li>Lytus Technologies Holdings PTV. Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lyt#NASDAQ">LYT</a>) shares jumped 92.8% to $0.1824 after falling 5% on Wednesday.</li>
<li>Agrify Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/agfy#NASDAQ">AGFY</a>) shares jumped 90% to $2.2401. Agrify said it entered into first Hydrocarbon Extraction Lab &amp; Vertical Farming unit facility in California.</li>
<li>Phunware, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/phun#NASDAQ">PHUN</a>) shares jumped 67.9% to $0.2730. Phunware shares dipped 61% on Wednesday after the company announced pricing of a $7 million registered direct offering price at-the-market under Nasdaq rules.</li>
<li>Celularity Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/celu#NASDAQ">CELU</a>) shares surged 43.4% to $0.2705 after falling more than 5% on Wednesday.</li>
<li>Marpai, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrai#NASDAQ">MRAI</a>) shares jumped 34.4% to $1.1359 after declining over 8% on Wednesday. Marpai recently named John Powers as President.</li>
<li>Akoustis Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/akts#NASDAQ">AKTS</a>) gained 21.7% to $0.7698.</li>
<li>Baijiayun Group Ltd (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rtc#NASDAQ">RTC</a>) gained 18.8% to $3.73.</li>
<li>M.D.C. Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mdc#NYSE">MDC</a>) rose 18.2% to $62.76 after the company announced it will be acquired by Sekisui House.</li>
<li>CURO Group Holdings Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/curo#NYSE">CURO</a>) gained 15.7% to $0.8499.</li>
<li>Lexeo Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lxeo#NASDAQ">LXEO</a>) rose 13% to $19.58.</li>
<li>Aurora Technology Acquisition Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/atak#NASDAQ">ATAK</a>) gained 13% to $4.79.</li>
<li>Acasti Pharma Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/acst#NASDAQ">ACST</a>) jumped 12.4% to $2.45.</li>
<li>Dada Nexus Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dada#NASDAQ">DADA</a>) gained 11.8% to $1.6750. Dada Nexus recently announced that it discovered suspicious practices in an internal audit.</li>
<li>Cadrenal Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cvkd#NASDAQ">CVKD</a>) surged 11.8% to $0.9499 after gaining over 7% on Wednesday.</li>
<li>Lanvin Group Holdings Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/lanv#NYSE">LANV</a>) jumped 9.3% to $2.5901.</li>
<li>LiveRamp Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ramp#NYSE">RAMP</a>) gained 9.2% to $40.30. LiveRamp Holdings said it sees preliminary third-quarter revenue of $174 million and announced plans to acquire Habu.</li>
<li>Roma Green Finance Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/roma#NASDAQ">ROMA</a>) surged 8.8% to $1.24 after tumbling over 70% on Wednesday.</li>
<li>Taiwan Semiconductor Manufacturing Company Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tsm#NYSE">TSM</a>) gained 8.1% to $111.26 after the company reported better-than-expected fourth-quarter financial results.</li>
<li>Hertz Global Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/htz#NASDAQ">HTZ</a>) gained 7.1% to $8.95 after Morgan Stanley upgraded the stock from Equal-Weight to Overweight but cut its price target form $16 to $15.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>Aravive, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/arav#NASDAQ">ARAV</a>) shares dipped 50.9% to $0.0542. Aravive intends to voluntarily terminate the listing of its common stock on the Nasdaq Global Select Market.</li>
<li>Processa Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pcsa#NASDAQ">PCSA</a>) fell 28.7% to $0.1975. Processa Pharmaceuticals said it will effect a 1-for-20 reverse stock split.</li>
<li>Newcourt Acquisition Corp (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ncac#NASDAQ">NCAC</a>) shares fell 27.3% to $8.43 after gaining around 12% on Wednesday.</li>
<li>Cano Health, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cano#NYSE">CANO</a>) dipped 26.4% to $1.76.</li>
<li>eHealth, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ehth#NASDAQ">EHTH</a>) fell 23.3% to $5.36. Craig-Hallum analyst George Sutton downgraded eHealth from Buy to Hold.</li>
<li>ZyVersa Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/zvsa#NASDAQ">ZVSA</a>) declined 23% to $0.53. ZyVersa Therapeutics recently announced the publication of an article in the peer-reviewed journal Acta Neuropathologica Communications, demonstrating that inflammasome activation enhances cancer metastasis to the brain in women with triple-negative breast cancer (TNBC).</li>
<li>ProQR Therapeutics N.V. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/prqr#NASDAQ">PRQR</a>) fell 20.4% to $2.2678.</li>
<li>Li-Cycle Holdings Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/licy#NYSE">LICY</a>) declined 18.5% to $0.4251.</li>
<li>LuxUrban Hotels Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/luxh#NASDAQ">LUXH</a>) fell 18% to $3.5430. LuxUrban responded to allegations in short seller report, highlighting mischaracterizations and speculation.</li>
<li>Nuvve Holding Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nvve#NASDAQ">NVVE</a>) shares fell 18.2% to $0.0830. Nuvve Holding will effect 1-for-40 reverse stock split, to be effective Jan. 19, 2024.</li>
<li>Zoomcar Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/zcar#NASDAQ">ZCAR</a>) fell 16.8% to $4.25. Zoomcar recently appointed Adarsh Menon as President.</li>
<li>QuantaSing Group Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/qsg#NASDAQ">QSG</a>) declined 16.4% to $2.5410. QuantaSing said it launched private label Chinese Baijiu brand YUNTING.</li>
<li>Cutera, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cutr#NASDAQ">CUTR</a>) fell 16% to $3.0601. Cutera recently reported preliminary FY23 revenue guidance above prior estimates.</li>
<li>Airspan Networks Holdings Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mimo#NASDAQ">MIMO</a>) shares declined 13.5% to $0.1900. Airspan shares jumped 186% on Wednesday after the company announced a partnership with GCT Semiconductor to develop an RF module.</li>
<li>Spirit Airlines, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/save#NYSE">SAVE</a>) fell 12.2% to $5.39 on continued downward momentum after a federal judge blocked JetBlue Airways from acquiring the company. Citigroup analyst Stephen Trent downgraded Spirit Airlines from Neutral to Sell and lowered the price target from $13 to $4.</li>
<li>Plug Power Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/plug#NASDAQ">PLUG</a>) shares dipped 12.1% to $2.4050 after the company announced it entered into an at market issuance sales agreement with B. Riley Securities for a common stock offering of up to $1 billion.</li>
<li>Meta Materials Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mmat#NASDAQ">MMAT</a>) shares declined 11.8% to $0.0673 after gaining 5% on Wednesday.</li>
<li>Humana Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hum#NYSE">HUM</a>) fell 11.5% to $396.49 after the company issued soft 2023 adjusted EPS guidance.</li>
<li>Fortuna Silver Mines Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/fsm#NYSE">FSM</a>) declined 11.2% to $3.14. Fortuna Silver Mines said fourth-quarter gold equivalent production rose 6% sequentially, while silver production fell 19% quarter-over-quarter.</li>
<li>Sify Technologies Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sify#NASDAQ">SIFY</a>) dipped 10.8% to $1.56 after the company reported worse-than-expected third-quarter sales results.</li>
<li>Nukkleus Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nukk#NASDAQ">NUKK</a>) fell 9.4% to $1.2510 after falling 6% on Wednesday. Nukkleus announced its intention to expand its investment in Jacobi Asset Management, known for sponsoring Europe&rsquo;s first approved Bitcoin spot ETF.</li>
<li>Mersana Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrsn#NASDAQ">MRSN</a>) dipped 8.3% to $2.65.</li>
<li>Discover Financial Services (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dfs#NYSE">DFS</a>) fell 6.9% to $101.22 after the company reported a 62% plunge in its profit for the fourth quarter on Wednesday.</li>
<li>U.S. Bancorp (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/usb#NYSE">USB</a>) slipped 3.7% to $39.31.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/01/36673023/jim-cramer-says-buy-this-utilities-stock-down-6-over-past-6-months-calls-bunge-a-battleg"> Jim Cramer Says Buy This Utilities Stock Down 6% Over Past 6 Months, Calls Bunge A &#39;Battleground&#39;</a>

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

ACST

AGFY

AKTS

ARAV

ATAK

CANO

CELU

CURO

CUTR

CVKD

DADA

EHTH

LANV

LICY

LUXH

LXEO

Airspan Networks Holdings Inc. Common Stock

MIMO

MMAT

MRAI

MRSN

NCAC

NUKK

NVVE

PCSA

PHUN

PLUG

RAMP

ROMA

SAVE

SIFY

ZCAR

ZVSA

Why KeyCorp Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Shares of Airspan Networks Holdings Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mimo#NASDAQ">MIMO</a>) shares rose sharply during Wednesday&rsquo;s session after the company announced a partnership with GCT Semiconductor to develop an RF module.
Airspan Networks Holdings shares surged 381% to $0.3699 on Wednesday.
Here are some other stocks moving in today&#39;s mid-day session.
<h3>Gainers</h3>
<ul>
<li>Treasure Global Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tgl#NASDAQ">TGL</a>) gained 31% to $0.1144.</li>
<li>LQR House Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lqr#NASDAQ">LQR</a>) gained 30.4% to $2.6344 after dipping 45% on Tuesday. LQR House announced an increase of its share buyback program to $5 million.</li>
<li>ProQR Therapeutics N.V. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/prqr#NASDAQ">PRQR</a>) rose 29% to $3.2123.</li>
<li>Safety Shot, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/shot#NASDAQ">SHOT</a>) climbed 26.7% to $2.2692. Safety Shot responded to FSD Pharma&#39;s unauthorized tagging of its stock and making false claims in an effort to harm the company and its shareholders.</li>
<li>Bullfrog AI Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bfrg#NASDAQ">BFRG</a>) gained 27% to $3.3626 after the company reported early results from its collaboration with Lieber Institute for Brain Development (LIBD).</li>
<li>Fitell Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ftel#NASDAQ">FTEL</a>) rose 25.7% to $1.2451.</li>
<li>Kintara Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ktra#NASDAQ">KTRA</a>) shares climbed 25.6% to $0.1594 after falling more than 9% on Tuesday.</li>
<li>Cognition Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cgtx#NASDAQ">CGTX</a>) gained 22.4% to $2.5339.</li>
<li>Rail Vision Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rvsn#NASDAQ">RVSN</a>) rose 22% to $2.0510 as the company said that a leading US-based rail and leasing services company signed a supply contract with Rail Vision valued at up to $5,000,000 for the purchase of Rail Vision&rsquo;s AI-based Switch Yard Systems.</li>
<li>Digital World Acquisition Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dwac#NASDAQ">DWAC</a>) jumped 17.5% to $26.25 after Donald Trump recently won the Iowa GOP caucus. Digital World Acquisition Corp is the business combination partner of Trump Media &amp; Technology Group.</li>
<li>American Coastal Insurance Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/acic#NASDAQ">ACIC</a>) gained 17.1% to $11.58 after Raymond James initiated coverage on the stock with an Outperform rating and announced a $15 price target.</li>
<li>Sinclair, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sbgi#NASDAQ">SBGI</a>) gained 13.6% to $15.47. Sinclair reached a preliminary agreement to settle the lawsuit filed by Diamond Sports Group, LLC (DSG) and its subsidiary Diamond Sports Net, LLC in July 2023.</li>
<li>Impinj, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pi#NASDAQ">PI</a>) surged 10.6% to $90.50 after the company reported preliminary revenue and adjusted EBITDA for the fourth quarter.</li>
<li>Liquidia Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lqda#NASDAQ">LQDA</a>) gained 10.4% to $13.67.</li>
<li>Maplebear Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cart#NASDAQ">CART</a>) gained 8.4% to $25.90 after Wolfe Research upgraded the stock from Peer Perform to Outperform and announced a $35 price target.</li>
<li>Progress Software Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/prgs#NASDAQ">PRGS</a>) rose 3.4% to $55.41 as the company posted stronger-than-expected results for its fourth quarter.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>TuSimple Holdings Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tsp#NASDAQ">TSP</a>) shares tumbled 54.7% to $0.3201 after the company announced its intention to delist from Nasdaq.</li>
<li>Phunware, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/phun#NASDAQ">PHUN</a>) fell 50% to $0.2099 after the company announced pricing of a $7 million registered direct offering price at-the-market under Nasdaq rules.</li>
<li>Adagene Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adag#NASDAQ">ADAG</a>) declined 46.5% to $2.03 after the company announced the presentation of ADG126 data.</li>
<li>TransCode Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rnaz#NASDAQ">RNAZ</a>) fell 32.6% to $2.5650.</li>
<li>Roma Green Finance Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/roma#NASDAQ">ROMA</a>) declined 31.5% to $2.68.</li>
<li>Remark Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mark#NASDAQ">MARK</a>) fell 27.7% to $0.4899.</li>
<li>Acurx Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/acxp#NASDAQ">ACXP</a>) fell 25.7% to $3.48. Acurx Pharmaceuticals released comparative microbiology and microbiome data for ibezapolstat, its lead antibiotic candidate, from its completed Phase 2b trial in patients with Clostridioides difficile Infection (CDI).</li>
<li>American Battery Technology Company (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/abat#NASDAQ">ABAT</a>) fell 25% to $2.45</li>
<li>Spirit Airlines, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/save#NYSE">SAVE</a>) shares dipped 24.1% to $6.01 on continued downward momentum after a federal judge blocked JetBlue Airways from acquiring the company.</li>
<li>New Horizon Aircraft Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hovr#NASDAQ">HOVR</a>) fell 22.6% to $2.60.</li>
<li>Charge Enterprises, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/crge#NASDAQ">CRGE</a>) fell 22.2% to $0.1260</li>
<li>Calavo Growers, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cvgw#NASDAQ">CVGW</a>) fell 15.4% to $24.56. Calavo Growers delayed release of its fourth-quarter and FY23 financial results.</li>
<li>Alector, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/alec#NASDAQ">ALEC</a>) declined 14.4% to $6.54 after the company announced the pricing of a $75 million public offering of 10,869,566 shares of common stock.</li>
<li>Fisker Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/fsr#NYSE">FSR</a>) fell 11.8% to $0.8519. TD Cowen analyst Jeffrey Osborne downgraded Fisker from Outperform to Market Perform and lowered the price target from $11 to $1.</li>
<li>Richtech Robotics Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rr#NASDAQ">RR</a>) fell 11.7% to $6.59.</li>
<li>LendingTree, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tree#NASDAQ">TREE</a>) shares tumbled 10.5% to $25.39.</li>
<li>Nukkleus Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nukk#NASDAQ">NUKK</a>) fell 9.3% to $1.36. Nukkleus signed MOU to increase holdings in Jacobi Asset Management.</li>
<li>Compass, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/comp#NYSE">COMP</a>) declined 8.8% to $2.9350.</li>
<li>Tellurian Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tell#NYSE">TELL</a>) fell 8.6% to $0.6126.</li>
<li>American Axle &amp; Manufacturing Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/axl#NYSE">AXL</a>) fell 8.1% to $7.34 after UBS downgraded the stock from Neutral to Sell and lowered its price target from $8 to $6.5.</li>
<li>Definitive Healthcare Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dh#NASDAQ">DH</a>) tumbled 8.1% to $8.45. Definitive Healthcare named Jason Krantz as Interim CEO, succeeding Robert Musslewhite.</li>
<li>10x Genomics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/txg#NASDAQ">TXG</a>) fell 7.8% to $41.04.</li>
<li>Esperion Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/espr#NASDAQ">ESPR</a>) dipped 6.9% to $2.6150.</li>
<li>HDFC Bank Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hdb#NYSE">HDB</a>) fell 6.8% to $56.99.</li>
<li>MINISO Group Holding Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mnso#NASDAQ">MNSO</a>) fell 6.8% to $21.00. MINISO shifted fiscal year end to Dec. 31 from June 30 for enhanced financial alignment.</li>
<li>DigitalOcean Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/docn#NYSE">DOCN</a>) declined 5.8% to $32.94. DigitalOcean named Paddy Srinivasan as Chief Executive Officer.</li>
<li>SolarEdge Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sedg#NASDAQ">SEDG</a>) fell 5.7% to $68.63 after Barclays downgraded the stock from Equal-Weight to Underweight and lowered its price target from $74 to $50.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/01/36653800/jim-cramer-says-hold-onto-this-biotech-stock-i-dont-understand-why-its-so-inexpensive"> Jim Cramer Says Hold Onto This Biotech Stock: &#39;I Don&#39;t Understand Why It&#39;s So Inexpensive&#39;</a>

ABAT

ACIC

ACXP

ADAG

ALEC

BFRG

CART

CGTX

COMP

CRGE

CVGW

DOCN

DWAC

ESPR

FTEL

HOVR

Kintara Therapeutics, Inc. - Common Stock

KTRA

LQDA

MARK

MNSO

PRGS

RNAZ

RVSN

SBGI

SEDG

SHOT

TELL

TREE

Why Airspan Networks Shares Are Trading Higher By Over 380%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

ProQR Therapeutics N.V. (PRQR) ASGCT Investor Webcast (Transcript)

ProQR (PRQR) has released an update. At ProQR Therapeutics N.V.'s 2024 annual general meeting, shareholders approved key resolutions including the ...

ProQR Shareholders Approve Key Resolutions

ProQR (PRQR) has released an update. ProQR Therapeutics N.V. has reported a decrease in total assets from €137,883 thousand at the end of 2023 to €...

ProQR Therapeutics N.V. Financial Performance Review

ProQR GAAP EPS of -€0.03, revenue of €6.31M

Analyst Jonathan Wolleben of JMP Securities reiterated a Buy rating on ProQR (PRQR – Research Report), retaining the price target of $5.00. Jonatha...

Buy Rating Affirmed: ProQR's Promising RNA-Editing Clinical and Preclinical Prospects

Chardan Capital analyst Keay Nakae has maintained their bullish stance on PRQR stock, giving a Buy rating yesterday. Keay Nakae has given his Buy r...

Optimistic Outlook for ProQR: Solid Financials and Promising Drug Pipeline Justify Buy Rating

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on SCYNEXIS (SCYX – Research Report), ProQR (PRQR – Res...

Wall Street Analysts Are Bullish on Top Healthcare Picks

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
ProQR Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/prqr-stock-quote/">PRQR</a>) just reported results for the second quarter of 2024.<ul><li>ProQR Therapeutics reported earnings per share of -3 cents. This was above the analyst estimate for EPS of -14 cents.</li><li>The company reported revenue of $6.79 million.</li><li>This was 45.74% worse than the analyst estimate for revenue of $12.51 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/prqr-stock-earnings-proqr-therapeutics-for-q2-of-2024/">PRQR Stock Earnings: ProQR Therapeutics Beats EPS, Misses Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

PRQR Stock Earnings: ProQR Therapeutics Beats EPS, Misses Revenue for Q2 2024

ProQR Therapeutics files for $300M mixed securities shelf

Wave stock soars 73% on positive data for RNA editing treatment (update)

GDRX

KRRO

SCYX

Press Releases

ProQR Announces Year End 2023 Operating and Financial Results

ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio

ProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual Meeting

ProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held May 22, 2024

ProQR Announces Preclinical Proof of Concept Data for AX-0810 Axiomer™ RNA Editing Program Targeting NTCP for Cholestatic Diseases

ProQR Announces First Quarter 2024 Operating and Financial Results

ProQR Announces Presentation on its Axiomer™ RNA Editing Technology at RNA Editing Summit

ProQR Announces Second Quarter 2024 Operating and Financial Results

ProQR Announces Webcast Presentation at the 2024 Cantor Global Healthcare Conference

ProQR Highlights Upcoming Presentation at 20th Annual Meeting of the Oligonucleotide Therapeutics Society

Comments

ProQR Therapeutics

Noticias

Últimas noticias sobre ProQR Therapeutics (NASDAQ:PRQR) Bolsa

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL